Ligand Pharmaceuticals Incorporated (LGND)
LGND moved a median of +0.06% 30 minutes after news, and +0.03% by the close. How LGND actually reacts to news — the realized, point-in-time move the market made, measured across 367 labeled events over the last three years with zero look-ahead.
LGND’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 33% | 363 |
| 30-min | +0.06% | 52% | 367 |
| 60-min | +0.15% | 54% | 367 |
| to close | +0.03% | 52% | 363 |
| Middle 50% of LGND reactions | -0.78% to +0.78% |
|---|---|
| Median reaction (30-min) | +0.06% |
| Measured reactions | 367 |
Half of all Ligand Pharmaceuticals Incorporated news events land between -0.78% and +0.78% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How LGND reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 19 | -0.40% | 32% | +0.39% |
| Rating reiterations | 67 | +0.20% | 66% | +0.32% |
| Price-target raises | 35 | 0.00% | 49% | -0.05% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how LGND ranks against every other measured name →
That’s how LGND usually reacts — get an email when it moves on news →Email me when LGND moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to LGND's baseline. Nothing else.
Recent LGND events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K LIGAND PHARMACEUTICALS For: Sep 24 | SEC filing · Form 8-K | SEC EDGAR | +0.42% | +0.70% | |
| Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million | Press release | GlobeNewswire | +0.42% | +0.70% | |
| Form 8-K LIGAND PHARMACEUTICALS For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | -0.52% | +2.58% | |
| Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million | Press release | GlobeNewswire | -0.52% | +2.58% | |
| Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners | Press release | PR Newswire | -0.52% | +2.58% | |
| Sydnexis Announces Royalty Agreement with Ligand for Ryjunea® | Press release | Business Wire | -0.52% | +2.58% | |
| Form 8-K/A LIGAND PHARMACEUTICALS For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | +1.10% | +0.98% | |
| Ligand to Participate in September Investor Conferences | Press release | GlobeNewswire | -1.67% | +2.18% | |
| Form 10-Q LIGAND PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.97% | — | |
| Form 8-K LIGAND PHARMACEUTICALS For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +1.29% | -1.94% | |
| Ligand Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +1.29% | -1.94% | |
| Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026 | Press release | GlobeNewswire | +0.59% | +0.56% | |
| Form S-8 LIGAND PHARMACEUTICALS | SEC filing · Form S-8 | SEC EDGAR | +0.59% | +0.56% | |
| Form 8-K LIGAND PHARMACEUTICALS For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | -0.31% | -2.68% | |
| Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets | Press release | GlobeNewswire | -0.31% | -2.68% | |
| Form 8-K LIGAND PHARMACEUTICALS For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | -2.91% | +3.07% | |
| Ligand Announces Closing of Convertible Senior Notes Offering | Press release | GlobeNewswire | -2.91% | +3.07% | |
| Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering | Press release | GlobeNewswire | +1.54% | +7.89% | |
| Form 8-K LIGAND PHARMACEUTICALS For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | -3.47% | -2.08% | |
| Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031 | Press release | GlobeNewswire | -3.47% | -2.08% | |
| Ligand Announces 2026 Investor Day in New York City | Press release | GlobeNewswire | +3.54% | +1.32% | |
| Form 8-K LIGAND PHARMACEUTICALS For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | +3.54% | +1.32% | |
| Ligand to Participate in June Investor Conferences | Press release | GlobeNewswire | -0.86% | +0.43% | |
| Form 8-K LIGAND PHARMACEUTICALS For: May 16 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.94% | |
| Form DEFA14A LIGAND PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -2.94% | |
| Form 10-Q LIGAND PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.54% | -0.42% | |
| Form 8-K LIGAND PHARMACEUTICALS For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +6.93% | +2.60% | |
| Ligand Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | +6.93% | +2.60% | |
| Ligand to Participate in May Investor Conferences | Press release | GlobeNewswire | +0.39% | -1.08% | |
| Form 8-K LIGAND PHARMACEUTICALS For: Apr 24 | SEC filing · Form 8-K | SEC EDGAR | -0.57% | -1.06% | |
| Form DEFA14A LIGAND PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | -0.40% | -4.65% | |
| ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation | Press release | PR Newswire | +0.41% | +1.31% | |
| Form 8-K LIGAND PHARMACEUTICALS For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | -3.65% | -0.86% | |
| Form DEFA14A LIGAND PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | +0.84% | +1.17% | |
| Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator | Press release | GlobeNewswire | -2.25% | +0.57% | |
| Ligand to Report First Quarter 2026 Financial Results on May 7, 2026 | Press release | GlobeNewswire | +0.00% | -0.51% | |
| Form ARS LIGAND PHARMACEUTICALS For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | -0.51% | |
| Form DEF 14A LIGAND PHARMACEUTICALS For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -0.51% | |
| Form DEFA14A LIGAND PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -0.51% | |
| Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS | Press release | GlobeNewswire | +1.09% | +5.61% | |
| Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team | Press release | GlobeNewswire | +0.48% | -0.63% | |
| Ligand to Participate in March Investor Conferences | Press release | GlobeNewswire | -1.83% | +2.00% | |
| Form 10-K LIGAND PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +2.71% | |
| Form S-3ASR LIGAND PHARMACEUTICALS | SEC filing · Form S-3ASR | SEC EDGAR | +0.00% | +2.71% | |
| Form 8-K LIGAND PHARMACEUTICALS For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -1.97% | +2.69% | |
| Ligand Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | -1.97% | +2.69% | |
| Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 | Press release | GlobeNewswire | +0.55% | -3.48% | |
| Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference | Press release | GlobeNewswire | -0.85% | -0.99% | |
| Form 8-K LIGAND PHARMACEUTICALS For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | +2.34% | +1.24% | |
| Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance | Press release | GlobeNewswire | -0.38% | -1.83% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the LGND section they belong to.
Where else LGND is measured.
LGND earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | 368 | -0.13% | 49% |
| Arcus Biosciences, Inc. (RCUS) | 368 | -0.09% | 45% |
| Microbot Medical Inc. (MBOT) | 366 | -0.19% | 43% |
| SOPHIRIS BIO INC (SPHS) | 366 | -0.23% | 37% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Ligand Pharmaceuticals Incorporated's median reaction calculated?
Every labeled LGND news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 367 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of LGND's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does LGND's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.